ECMO is indicated in case of potentially reversible cardio(respiratory) failure refractory to conventional therapies. It can be divided in two main groups: the respiratory indications (e.g. acute respiratory distress syndrome), for which veno-venous ECMO is indicated
Conditions
Interventions
None listed
Sponsors
None listed
Eligibility
Inclusion criteria
Inclusion criteria: Patients were included in the study if: - They were admitted to the Intensive Care Unit (ICU) between January 1st 2018 up to July 1st 2019; AND - They received support from extracorporeal membrane oxygenation (ECMO) during their ICU admission; AND - They were aged 18 years and older.
Exclusion criteria
Exclusion criteria: Patients were excluded in the study if: - The total duration of ECMO support was less than 24 hours.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary outcome is the total and daily amount of transfusion of blood products (red blood cells, platelets, plasma) and tranexamic acid, fibrinogen and prothrombin complex concentrate, received by patients on ECMO up to 28 days of support. Furthermore, clinical variables that may be associated with the occurrence of transfusion and a higher amount of transfusions will be evaluated. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary outcomes are the 28-day mortality (calculated as from ECMO initiation) and complication rate (hemorrhage, thrombosis, infection, acute kidney injury). | — |
Contacts
Public ContactAlexander Vlaar
Amsterdam UMC, location AMC
Outcome results
None listed